Keyuan Petrochemicals (OTCMKTS:KEYP – Get Free Report) and Codexis (NASDAQ:CDXS – Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.
Analyst Ratings
This is a summary of current ratings for Keyuan Petrochemicals and Codexis, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Keyuan Petrochemicals | 0 | 0 | 0 | 0 | 0.00 |
Codexis | 0 | 1 | 2 | 0 | 2.67 |
Codexis has a consensus price target of $8.33, indicating a potential upside of 201.93%. Given Codexis’ stronger consensus rating and higher possible upside, analysts plainly believe Codexis is more favorable than Keyuan Petrochemicals.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Keyuan Petrochemicals | N/A | N/A | N/A |
Codexis | -96.35% | -71.56% | -38.00% |
Earnings and Valuation
This table compares Keyuan Petrochemicals and Codexis”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Keyuan Petrochemicals | N/A | N/A | N/A | N/A | N/A |
Codexis | $59.35 million | 3.85 | -$76.24 million | ($0.90) | -3.07 |
Keyuan Petrochemicals has higher earnings, but lower revenue than Codexis.
Institutional & Insider Ownership
78.5% of Codexis shares are owned by institutional investors. 2.1% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Codexis beats Keyuan Petrochemicals on 6 of the 9 factors compared between the two stocks.
About Keyuan Petrochemicals
Keyuan Petrochemicals, Inc., through its subsidiaries, Ningbo Keyuan, Ningbo Keyuan Petrochemicals, Keyuan Synthetic Rubbers, Guangxi Keyuan and Zhongkexuneng, is engaged in the manufacture and sale of petrochemical products and rubber in the People’s Republic of China. The Company’s segments include the manufacture and sale of petrochemical products (petrochemical segment) and the manufacture and sale of rubber products (rubber segment). The Petrochemicals Segment includes the manufacturing and sales of mixed light aromatics, mixed heavy aromatics, fine propylene, propane, butane, liquefied petroleum gas (LPG), methyltert-butylether and styrene. The Rubber Segment includes the manufacturing and sales of various rubber products. It manufactures and supplies various petrochemical and rubber products, including petrochemical products, such as Benzene Toluene-Xylene Aromatics (BTX Aromatics), propylene, styrene, LPG, Methyl Tertiary Butyl Ether (MTBE) and rubber products.
About Codexis
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Receive News & Ratings for Keyuan Petrochemicals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keyuan Petrochemicals and related companies with MarketBeat.com's FREE daily email newsletter.